Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
A closely watched heart drug from Amgen and Cytokinetics has both hit the primary endpoint on a major trial and dramatically disappointed investors.
In the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
